-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Siludi Pharmaceutical Co., Ltd. (01244) rose more than 14%. Partner SELLAS cancer vaccine GPS successfully treated AML phase III

Zhitongcaijing·11/18/2026 03:41:03
Listen to the news

The Zhitong Finance App learned that Siludi Pharmaceutical Co., Ltd. (01244) rose by more than 14%. As of press release, it had risen 14.23% to HK$2.85, with a turnover of HK$657,900.

According to the news, on November 17, the US biopharmaceutical company Sellas Life Sciences announced that the cancer vaccine GPS reached the main OS endpoint in AML phase III clinical Regal, with a 41% reduction in the risk of death. The MOS for the treatment group and control group was 24.0 months and 14.7 months, respectively. Affected by this, the company's stock price skyrocketed by more than 233% overnight, the highest level since June 2019.

According to reports, Siludi Pharmaceutical reached a cooperation with SELLAS in December 2020 to obtain exclusive development and commercialization rights for the 3D189 and its seven-price upgrade GPS+ for all indications in Greater China. The company announced on October 29 that if approved, 3D189 will become the world's first WT1 tumor vaccine. SELLAS said the company plans to meet with the US Food and Drug Administration (FDA) to discuss accelerated filing strategies.